Reduced efficacy of multiple doses of CpG-matured dendritic cell tumor vaccine in an experimental model
- Arash Pourgholaminejad,
- Arezoo Jamali,
- Morteza Samadi-Foroushani,
- Afshin Amari,
- Reza Mirzaei,
- Bita Ansaripour
- Tehran University of Medical Sciences,
- Shaheed Sadughi University of Medical Sciences,
- Pasteur Institute of Iran,
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
CpG motifs have been advanced as agents that stimulate the maturation of DCs for immunotherapy. The present study tested the hypothesis that multiple doses of CpG-matured DC vaccine would be efficacious for complete eradication of experimentally-induced tumor. Accordingly, WEHI164 cells were implanted subcutaneously in the flank of BALB/c mice. During DC culture, tumor lysate was added to immature DCs followed by addition of CpG or non-CpG control 4-6 h later. A total of three doses of CpG or non-CpG control-matured DCs were injected around tumors. The results showed that multiple doses of CpG-matured DCs led to considerable decrease in cytotoxicity of lymphocytes and significantly increased tumor growth rate compared to a single dose. Further, mice which received three doses of the vaccine also displayed significant FoxP3 in tumor tissue. In conclusion, multiple doses of CpG-matured DCs exhibited decreased anti-tumor immunity in association with increased expression of FoxP3.
Publication Information
Output type
Original language
English (US)Pages from-to (Number of pages)
Pages 360-364 (5 pages)Journal (Volume, Issue Number)
Cellular Immunology (Volume 271, Issue 2)Publication milestones
- Published - 2011
Publication status
ISSN
0008-8749Publication IDs
- Scopus: 80054020585
- PubMed: 21889129
